AML
Conference Coverage
Antibody-drug conjugate boasts high remission rates in AML
Among older adults with acute myeloid leukemia, the combination of a drug-antibody conjugate and hypomethylating therapy was associated with high...
Conference Coverage
Persistent post-therapy mutations may spark AML relapse
The higher risk of acute myeloid leukemia relapse among older patients may be due to persistent pre-leukemic mutations.
Conference Coverage
Venetoclax + LDAC has potential in older AML patients
CHICAGO—Investigators are pursuing the combination of the selective BCL-2 inhibitor venetoclax plus low-dose cytarabine (LDAC) in older, treatment...
Conference Coverage
VIDEO: CPX-351 ‘new standard of care’ for older patients with secondary AML
News
Ingredient in aspirin may help fight leukemia
Photo credit: Jill Watson Researchers say they may have found a new use for an ancient anti-inflammatory drug, salicylate, which was first...
News
AYAs still fare worse than kids with leukemia, lymphoma
patient and her father Photo by Rhoda Baer Adolescents and young adults (AYAs) are less likely than children to survive 8 relatively common types...
Conference Coverage
Dr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016
News
Team simplifies synthesis of anticancer agent
Photo courtesy of Jeff Fitlow and Rice University Researchers say they have streamlined synthesis of delta12-prostaglandin J3, a molecule that...
News
Drug granted breakthrough designation for AML
Image by Lance Liotta The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for CPX-351 (Vyxeos), a fixed-ratio...
News
Breast cancer drug could treat AML
(below) palbociclib treatment Images courtesy of Iris Uras and Vetmeduni Vienna Palbociclib, a CDK4/6 kinase inhibitor approved to treat breast...